<figure><div><img src="https://imgproxy.divecdn.com/LOS_28-DMajSa8O6Kljhq6j2s2eQ9vRkHn46DVb8jQ4/g:nowe:0:1261/c:8000:4520/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDM5OTA3NDhfb1VYZnlvYi5qcGc=.webp"/></div></figure><p>The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.</p>
<figure><div><img src="https://imgproxy.divecdn.com/94XJqjEuU8Sh3O5ntWXwEkkZsr-HX16AShICo3wJ6gM/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg2NTMwODkwLmpwZw==.webp"/></div></figure><p>Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.</p>
<figure><div><img src="https://imgproxy.divecdn.com/X7DgF8XHrG_MI3bhvzEYolMGhzhwM6NirOEKG8Pfs7c/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjc5NTI1NjM3LmpwZw==.webp"/></div></figure><p>Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.</p>
<figure><div><img src="https://imgproxy.divecdn.com/Jf1gO7ioRryvnvK0xR_BifCR-vvKQ0xHeNannXjzN3g/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjYtMDQtMTZfYXRfMS40OS4xM19QTS5wbmc=.webp"/></div></figure><p>Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.</p>
<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDgzOTIxNzkzLmpwZw==.webp"/></div></figure><p>Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.</p>
<figure><div><img src="https://imgproxy.divecdn.com/Hnh1jrlLIHR3bfdeqaxMAELwGbp4qjrJ6ilikxCSU3c/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTYxMTAxOTY4LmpwZw==.webp"/></div></figure><p>Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.</p>
<figure><div><img src="https://imgproxy.divecdn.com/noY6Oanv5v-_yDQZKEqBBDkEKvecYGoj9vaCkgyW_q0/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjgxODMyMjUyX20yY2w4SnouanBn.webp"/></div></figure><p>Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.</p>
<figure><div><img src="https://imgproxy.divecdn.com/bHeki-RcmamHWZ337AesYqx0-vgLVnsXCVdnZnNyTHA/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjQ0MTEwNTU2LmpwZw==.webp"/></div></figure><p>Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.</p>
<p>The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.</p>
<figure><div><img src="https://imgproxy.divecdn.com/e5hIA-Hiprl5UY3oaP3-AtC6qQcq5UNFKsXjebwncaY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjg5OTA0MzY2LmpwZw==.webp"/></div></figure><p>The executive order — which wasn’t accompanied by any new scientific evidence — aims to split the MMR vaccine into three separate shots and revives the administration’s attempt to slim down the immunization schedule.</p>